Skip Navigation

European Journal of Heart Failure 2005 7(1):57-61; doi:10.1016/j.ejheart.2004.04.009
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Faggiano, P.
Right arrow Articles by Cas, L. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faggiano, P.
Right arrow Articles by Cas, L. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society of Cardiology

Serum levels of different tumour markers in patients with chronic heart failure

Pompilio Faggiano*, Antonio D'Aloia, Loretta Brentana, Tommaso Bignotti, Claudia Fiorina, Enrico Vizzardi and Livio Dei Cas

Cattedra di Cardiologia, Università di Brescia Unità Operativa di Policardiografia e di Cardiologia Spedali Civili, Via S. Antonio 6, 25133 Brescia, Italy

* Corresponding author. Fax: +39-030-2007785. E-mail address: faggiano{at}numerica.it


   Abstract

Background: serum levels of carbohydratic antigen 125 (CA 125), a tumour marker related to ovarian cancer, are increased in patients with heart failure (CHF). To our knowledge there are no data concerning the levels of other tumour markers in CHF.

Methods: we measured serum levels of Alpha-Fetoprotein (AFP), Carcinoembrionic antigen (CEA), CA 19.9, CA 15.3 and CA 125, in 191 pts (86 males, mean age 67±10 years) with mild to severe CHF due to left ventricular systolic dysfunction.

Results: Only CA-125 was increased in CHF patients: mean values were significantly higher (P<0.05) in NYHA classes III (60±22 UI/ml) and IV (192±115 UI/ml) compared to NYHA class I-II patients (16±11). Mean values of the other tumor markers were within the normal range. AFP was above the upper normal limit in 2/191 patients (1%), CEA in 5/191 (2.6%), CA 19.9 in 0, CA 15.3 in 2/191 (1%) and CA 125 in 126/191 patients (66%). In 30 NYHA IV patients, tumour markers were repeated after 5–20 days of aggressive medical treatment, when a clinical improvement (reduction of at least 1 NYHA class) was reached: mean serum levels of CA 125 decreased from 107±85 to 19±8 U/ml (P<0.05); no changes in other tumour markers were observed.

Conclusions: Of the tumour markers evaluated, only CA 125 seems to be related to the presence and severity of CHF and shows significant changes in response to medical therapy. The biologic and clinical relevance of this observation needs to be defined.

Key Words: Heart failure • Tumour markers • Carbohydrate antigen-125

Received October 24, 2003; Revised February 9, 2004; Accepted April 7, 2004


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
D. Duman, F. Palit, E. Simsek, and K. Bilgehan
Serum carbohydrate antigen 125 levels in advanced heart failure: Relation to B-type natriuretic peptide and left atrial volume
Eur J Heart Fail, June 1, 2008; 10(6): 556 - 559.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J. Nunez, E. Nunez, L. Consuegra, J. Sanchis, V. Bodi, A. Martinez-Brotons, V. Bertomeu-Gonzalez, R. Robles, M. J Bosch, L. Facila, et al.
Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure?
Heart, June 1, 2007; 93(6): 716 - 721.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.